Propylthiouracil and hepatitis. Two cases and a review of the literature.
Propylthiouracil-induced hepatitis is an uncommon entity. Two further cases are reported herein, and the clinical and laboratory features of the other six cases in the English literature are reviewed. The initial appearance of the disease is similar to that of viral hepatitis, characterized by nausea, vomiting, and jaundice. The biochemical pattern of injury is predominantly hepatocellular, with marked elevation of transaminase valves and less striking elevation of alkaline phosphatase values. Recovery is usually complete after withdrawal of the drug, but there have been at least two fatalities, including the first patient (to our knowledge) whose case is reported herein. Despite its rarity, the disease should be suspected in any patient receiving propylthiouracil in whom clinical or laboratory evidence of hepatocellular injury develops.
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology*; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D006111:Graves Disease / Q000188:drug therapy; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006525:Hepatitis, Viral, Human / Q000175:diagnosis; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011441:Propylthiouracil / Q000009:adverse effects* / Q000627:therapeutic use; D012698:Serologic Tests
D000974:Antibodies, Antinuclear; D006514:Hepatitis B Surface Antigens; D011441:Propylthiouracil